Emtricitabine/rilpivirine/tenofovir alafenamide

Drug Profile

Emtricitabine/rilpivirine/tenofovir alafenamide

Alternative Names: FTC/RPV/TAF; Odefsey; R/F/TAF; Rilpivirine/emtricitabine/tenofovir alafenamide; Tenofovir alafenamide/rilpivirine/emtricitabine

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences; Janssen
  • Class Antiretrovirals; Deoxyribonucleosides; Nitriles; Purines; Pyrimidine nucleosides; Pyrimidines; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 04 Oct 2017 Efficacy data from a phase III trial in HIV-1 infections presented at the IDWeek 2017
  • 16 Feb 2017 Registered for HIV-1 infections (Treatment-experienced) in Canada (PO)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top